Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.70 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.70 |
| ▸ | CETP | P11597 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150942 | 0.98 | CYP4F2 (0.72) | CYP4F2CYP4A11CETPNPSR1NAAA | |
| SCHEMBL28199817 | 0.95 | CYP4F2 (0.67) | CYP4F2CYP4A11CETPNPSR1NAAA | |
| SCHEMBL11088776 | 0.93 | CYP4F2 (0.69) | CYP4F2CYP4A11CETPNPSR1NAAA | |
| SCHEMBL4944314 | 0.89 | CYP4F2 (0.64) | CYP4F2CYP4A11CETPNPSR1NAAA | |
| Azetidine SCHEMBL28846888 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11CETPNPSR1NAAA | |
| SCHEMBL23309175 | 0.86 | CYP4F2 (0.93) | CYP4F2CYP4A11CETPNPSR1MAPT | |
| SCHEMBL11230109 | 0.86 | CYP4F2 (0.56) | CYP4F2CYP4A11CETPNAAA | |
| SCHEMBL20730090 | 0.84 | CYP4F2 (0.97) | CYP4F2CYP4A11CETPNPSR1EPHX1 | |
| SCHEMBL22070954 | 0.84 | CYP4F2 (0.96) | CYP4F2CYP4A11CETPNPSR1MAPT | |
| Pyrrolidine SCHEMBL28846861 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11CETPNPSR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528907-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | Allergan, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | TUBB6, ANXA5, TUBB1 | CYP4F2 1791/4885CYP4A11 232/4885CETP 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.